Found 24 matching trials
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. PHASE1 The purpose of this study is to evaluate the change in the expression of tr...
Show More Status
Active Not Recruiting
Location
Nebraska Cancer Specialists
Learn More & Join Trial
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) PHASE2 In advanced metastatic castration resistant prostate cancer (mCRPC) progres...
Show More Location
UCLA / Jonsson Comprehensive Cancer Center
Learn More & Join Trial
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan PHASE2 The purpose of this study is to assess the efficacy, tolerability, safety, ...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer PHASE1 This phase I trial compares the effect of lutetium Lu 177 (177\^Lu)-prostat...
Show More Location
City of Hope Medical Center
Learn More & Join Trial
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer PHASE3 This phase III study provides access to 68Ga-PSMA-11 positron emission tomo...
Show More Location
Mayo Clinic in Rochester
Learn More & Join Trial
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer PHASE2 This phase II trial studies how to improve the usage of Lu 177 vipivotide t...
Show More Location
Mayo Clinic in Rochester
Learn More & Join Trial
Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer PHASE1 This phase I trial studies the safety, side effects, and treatment cycle 1 ...
Show More Location
University of Michigan Rogel Cancer Center
Learn More & Join Trial
Evaluation of the Concordance Between Pre-therapy Dosimetry Performed From 68Ga-PSMA-11 Dynamic PET and Post-treatment Dosimetry of 177Lu-PSMA-617 Vectorized Internal Radiotherapy in Patients With Metastatic Prostate Cancer Resistant to Hormonal Castration. NA Patients undergo three diagnostic PET scans: 18F-FDG PET scan / 18F-Choline...
Show More Location
Multiple Locations
Learn More & Join Trial
Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617 NA Renal Cell Carcinoma (RCC) is the second most common tumor in urology. Cons...
Show More Location
Peking Union Medical College Hospital
Learn More & Join Trial
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer PHASE4 This a single-center, prospective, exploratory study. Patients with metasta...
Show More Location
VA Greater Los Angeles Healthcare System
Learn More & Join Trial